Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 552Neoplasms 502Carcinoma, Non-Small-Cell Lung 419Prostatic Neoplasms 326Colorectal Neoplasms 310Lung Neoplasms 280Neoplasm Metastasis 233Leukemia, Myeloid, Acute 222Ovarian Neoplasms 205Pancreatic Neoplasms 195Multiple Myeloma 186Recurrence 141Squamous Cell Carcinoma of Head and Neck 140Brain Neoplasms 139Stomach Neoplasms 138Melanoma 132Carcinoma, Hepatocellular 130Endometrial Neoplasms 127Glioblastoma 124Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 102Head and Neck Neoplasms 100Urinary Bladder Neoplasms 98Carcinoma, Renal Cell 98Lymphoma 97Glioma 94Sarcoma 93Esophageal Neoplasms 90Uterine Cervical Neoplasms 88

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sinonasal Squamous Cell Carcinoma × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡